Guangying Wang

Conflicts of Interest The authors declare no conflicts of interest. Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request. References 1, , , and , “The Emergence and Prospects of Deep-Ultraviolet Light-Emitting Diode Technologies,” Nature Photonics 13, no. 4 (2019): 233–244. 2, , , et al., “The 2020 UV Emitter Roadmap,” Journal of Physics D: Applied Physics 53, no. 50 (2020): 503001.

Review Article Electrocardiographic changes in immune checkpoint inhibitor-associated cardiac injury: a narrative review Shaqi Rao, Guangying Wang, Jinjing Wu, Jiawei Ouyang, Zhuoqi Liu, Xiaohong Yang, Daya Luo, Shuhua Zhang Abstract Immune checkpoint inhibitors (ICIs) are widely used in cancer treatment and have shown substantial clinical benefit. Although the incidence of ICI-associated cardiac injury is uncommon, such events may lead to severe complications and high mortality.

Abstract Immune checkpoint inhibitors (ICIs) have revolutionized the therapeutic landscape of diverse solid tumors; however, concurrent viral infections significantly influence their efficacy and safety profiles. By driving persistent antigen exposure, inducing T cell exhaustion, and remodeling the immunosuppressive tumor microenvironment (TME), viruses extensively reconfigure tumor immune landscapes, leading to marked heterogeneity in responses to immunotherapy.